157 related articles for article (PubMed ID: 29661166)
1. High OX40 expression in recurrent ovarian carcinoma is indicative for response to repeated chemotherapy.
Ramser M; Eichelberger S; Däster S; Weixler B; Kraljević M; Mechera R; Tampakis A; Delko T; Güth U; Stadlmann S; Terracciano L; Droeser RA; Singer G
BMC Cancer; 2018 Apr; 18(1):425. PubMed ID: 29661166
[TBL] [Abstract][Full Text] [Related]
2. MPO density in primary cancer biopsies of ovarian carcinoma enhances the indicative value of IL-17 for chemosensitivity.
Droeser RA; Mechera R; Däster S; Weixler B; Kraljević M; Delko T; Güth U; Stadlmann S; Terracciano L; Singer G
BMC Cancer; 2016 Aug; 16():639. PubMed ID: 27531373
[TBL] [Abstract][Full Text] [Related]
3. High IL-17-positive tumor immune cell infiltration is indicative for chemosensitivity of ovarian carcinoma.
Droeser RA; Güth U; Eppenberger-Castori S; Stadlmann S; Hirt C; Terracciano L; Singer G
J Cancer Res Clin Oncol; 2013 Aug; 139(8):1295-302. PubMed ID: 23624523
[TBL] [Abstract][Full Text] [Related]
4. High ratio of pCXCR4/CXCR4 tumor infiltrating immune cells in primary high grade ovarian cancer is indicative for response to chemotherapy.
Walther F; Berther JL; Lalos A; Ramser M; Eichelberger S; Mechera R; Soysal S; Muenst S; Posabella A; Güth U; Stadlmann S; Terracciano L; Droeser RA; Zeindler J; Singer G
BMC Cancer; 2022 Apr; 22(1):376. PubMed ID: 35397601
[TBL] [Abstract][Full Text] [Related]
5. High density of CD66b in primary high-grade ovarian cancer independently predicts response to chemotherapy.
Posabella A; Köhn P; Lalos A; Wilhelm A; Mechera R; Soysal S; Muenst S; Güth U; Stadlmann S; Terracciano L; Droeser RA; Zeindler J; Singer G
J Cancer Res Clin Oncol; 2020 Jan; 146(1):127-136. PubMed ID: 31853662
[TBL] [Abstract][Full Text] [Related]
6. High Density of CD16+ Tumor-Infiltrating Immune Cells in Recurrent Ovarian Cancer Is Associated with Enhanced Responsiveness to Chemotherapy and Prolonged Overall Survival.
Lalos A; Neri O; Ercan C; Wilhelm A; Staubli S; Posabella A; Weixler B; Terracciano L; Piscuoglio S; Stadlmann S; Spagnoli GC; Droeser RA; Singer G
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830938
[TBL] [Abstract][Full Text] [Related]
7. OX40 expression enhances the prognostic significance of CD8 positive lymphocyte infiltration in colorectal cancer.
Weixler B; Cremonesi E; Sorge R; Muraro MG; Delko T; Nebiker CA; Däster S; Governa V; Amicarella F; Soysal SD; Kettelhack C; von Holzen UW; Eppenberger-Castori S; Spagnoli GC; Oertli D; Iezzi G; Terracciano L; Tornillo L; Sconocchia G; Droeser RA
Oncotarget; 2015 Nov; 6(35):37588-99. PubMed ID: 26439988
[TBL] [Abstract][Full Text] [Related]
8. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.
Trimbos JB; Vergote I; Bolis G; Vermorken JB; Mangioni C; Madronal C; Franchi M; Tateo S; Zanetta G; Scarfone G; Giurgea L; Timmers P; Coens C; Pecorelli S;
J Natl Cancer Inst; 2003 Jan; 95(2):113-25. PubMed ID: 12529344
[TBL] [Abstract][Full Text] [Related]
9. The expression of DBC1/CCAR2 is associated with poor prognosis of ovarian carcinoma.
Cho D; Park H; Park SH; Kim K; Chung M; Moon W; Kang M; Jang K
J Ovarian Res; 2015 Feb; 8():2. PubMed ID: 25823848
[TBL] [Abstract][Full Text] [Related]
10. High density of CXCL12-positive immune cell infiltration predicts chemosensitivity and recurrence-free survival in ovarian carcinoma.
Köhn P; Lalos A; Posabella A; Wilhelm A; Tampakis A; Caner E; Güth U; Stadlmann S; Spagnoli GC; Piscuoglio S; Richarz S; Delko T; Droeser RA; Singer G
J Cancer Res Clin Oncol; 2023 Dec; 149(20):17943-17955. PubMed ID: 37966614
[TBL] [Abstract][Full Text] [Related]
11. Aurora-B protein expression is linked to initial response to taxane-based first-line chemotherapy in stage III ovarian carcinoma.
Beussel S; Hasenburg A; Bogatyreva L; Hauschke D; Werner M; Lassmann S
J Clin Pathol; 2012 Jan; 65(1):29-35. PubMed ID: 22011448
[TBL] [Abstract][Full Text] [Related]
12. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma.
Trimbos JB; Parmar M; Vergote I; Guthrie D; Bolis G; Colombo N; Vermorken JB; Torri V; Mangioni C; Pecorelli S; Lissoni A; Swart AM; ;
J Natl Cancer Inst; 2003 Jan; 95(2):105-12. PubMed ID: 12529343
[TBL] [Abstract][Full Text] [Related]
13. Expression of the chromatin remodeling factor Rsf-1 is upregulated in ovarian carcinoma effusions and predicts poor survival.
Davidson B; Trope' CG; Wang TL; Shih IeM
Gynecol Oncol; 2006 Dec; 103(3):814-9. PubMed ID: 16844205
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.
Darb-Esfahani S; Kunze CA; Kulbe H; Sehouli J; Wienert S; Lindner J; Budczies J; Bockmayr M; Dietel M; Denkert C; Braicu I; Jöhrens K
Oncotarget; 2016 Jan; 7(2):1486-99. PubMed ID: 26625204
[TBL] [Abstract][Full Text] [Related]
15. [Epithelial ovarian cancer].
Hilpert F; Krause G; Venhoff L; Kühnle E; Schem C; Maass N
Ther Umsch; 2007 Jul; 64(7):375-80. PubMed ID: 17948754
[TBL] [Abstract][Full Text] [Related]
16. Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma.
Liu Y; Yasukawa M; Chen K; Hu L; Broaddus RR; Ding L; Mardis ER; Spellman P; Levine DA; Mills GB; Shmulevich I; Sood AK; Zhang W
JAMA Oncol; 2015 Jul; 1(4):486-94. PubMed ID: 26181259
[TBL] [Abstract][Full Text] [Related]
17. External validation of chemotherapy response score system for histopathological assessment of tumor regression after neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma.
Lee JY; Chung YS; Na K; Kim HM; Park CK; Nam EJ; Kim S; Kim SW; Kim YT; Kim HS
J Gynecol Oncol; 2017 Nov; 28(6):e73. PubMed ID: 28758379
[TBL] [Abstract][Full Text] [Related]
18. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
19. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
du Bois A; Kristensen G; Ray-Coquard I; Reuss A; Pignata S; Colombo N; Denison U; Vergote I; Del Campo JM; Ottevanger P; Heubner M; Minarik T; Sevin E; de Gregorio N; Bidziński M; Pfisterer J; Malander S; Hilpert F; Mirza MR; Scambia G; Meier W; Nicoletto MO; Bjørge L; Lortholary A; Sailer MO; Merger M; Harter P;
Lancet Oncol; 2016 Jan; 17(1):78-89. PubMed ID: 26590673
[TBL] [Abstract][Full Text] [Related]
20. Increased cyclooxygenase-2 (COX-2) and P-glycoprotein-170 (MDR1) expression is associated with chemotherapy resistance and poor prognosis. Analysis in ovarian carcinoma patients with low and high survival.
Raspollini MR; Amunni G; Villanucci A; Boddi V; Taddei GL
Int J Gynecol Cancer; 2005; 15(2):255-60. PubMed ID: 15823108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
